Abstract:Patients with myocardial ischemia and infarction are at increased risk of arrhythmias, which in turn, can exacerbate the overall risk of mortality. Despite the observed reduction in recurrent arrhythmias through antiarrhythmic drug therapy, the precise mechanisms underlying their effectiveness in treating ischemic heart disease remain unclear. Moreover, there is a lack of specialized drugs designed explicitly for the treatment of myocardial ischemic arrhythmia. This study employs an electrophysiological simulation approach to investigate the potential antiarrhythmic effects and underlying mechanisms of various pharmacological agents in the context of ischemia and myocardial infarction (MI). Based on physiological experimental data, computational models are developed to simulate the effects of a series of pharmacological agents (amiodarone, telmisartan, E-4031, chromanol 293B, and glibenclamide) on cellular electrophysiology and utilized to further evaluate their antiarrhythmic effectiveness during ischemia. On 2D and 3D tissues with multiple pathological conditions, the simulation results indicate that the antiarrhythmic effect of glibenclamide is primarily attributed to the suppression of efflux of potassium ion to facilitate the restitution of [K + ] o , as opposed to recovery of I KATP during myocardial ischemia. This discovery implies that, during acute cardiac ischemia, pro-arrhythmogenic alterations in cardiac tissue's excitability and conduction properties are more significantly influenced by electrophysiological changes in the depolarization rate, as opposed to variations in the action potential duration (APD). These findings offer specific insights into potentially effective targets for investigating ischemic arrhythmias, providing significant guidance for clinical interventions in acute coronary syndrome. In acute coronary syndrome, the progression of ischemic, injury, and infarction conditions heightens the risk of ischemic cardiac arrhythmias. Despite the existence of various antiarrhythmic drugs, there remains a scarcity of medications specifically tailored for ischemic cardiac arrhythmias. Moreover, comprehending the diverse drug responses in tissues with multiple ischemic conditions (ischemia 1a, 1b, and infarction) remains incomplete. Therefore, in this study, mathematical models depicting the electrophysiological remodeling induced by different drugs such as amiodarone, telmisartan, E-4031, chromanol 293B, and glibenclamide, are constructed and integrated into multi-scale computational models to assess their antiarrhythmic effects. Simulation results demonstrate the potential of glibenclamide in mitigating ischemic cardiac arrhythmias. It can be attributed to its ability not only to improve the depolarization phase's membrane potential by inhibiting extracellular potassium accumulation during the ischemic stage, leading to an increased dV/dt max , but also to extend the action potential duration (APD) by suppressing I KATP . Finally, the application of glibenclamide results in heightened conduction velocity and prolonged APD at the tissue level. Consequently, these effects enlarge the wavelength of excitation waves, ultimately reducing the vulnerable window for reentrant wave and exhibiting an anti-ischemic arrhythmic effect. More importantly, it's shown that glibenclamide's inhibition of [K + ] o yields a more significant impact on antiarrhythmic effects compared to its prolongation of APD. This is partly due to the more pronounced enhancement in the wavelength of excitation waves resulting from CV elevation compared with APD prolongation. Additionally, in tissues with coexisting multiple ischemic conditions, suppressing [K + ] o reduces the spatial dispersion of CV, especially at the boundaries of different ischemic tissues like ischemia 1b and infarction, facilitating a more uniform excitation wave propagation. This study offers insights into the anti-arrhythmic mechanisms of established agents during acute coronary syndrome and identifies potential targets for novel anti-arrhythmic drug development.

Mechanisms of Action of Antiarrhythmic Drugs

Cardiac arrhythmogenesis: roles of ion channels and their functional modification

Pharmacotherapy in Ventricular Arrhythmias

The Role of Biologically Active Ingredients from Natural Drug Treatments for Arrhythmias in Different Mechanisms

Model systems for the discovery and development of antiarrhythmic drugs

Drug Interactions Affecting Antiarrhythmic Drug Use

Mechanisms Underlying the Antiarrhythmic Action of Compound ALM-802

Theoretical possibilities for the development of novel antiarrhythmic drugs

A general mechanism for drug promiscuity: Studies with amiodarone and other antiarrhythmics

The characteristics and molecular targets of antiarrhythmic natural products

The ion channel basis of pharmacological effects of amiodarone on myocardial electrophysiological properties, a comprehensive review

A simulation study on the antiarrhythmic mechanisms of established agents in myocardial ischemia and infarction

Novel approaches for pharmacological management of atrial fibrillation

Inhibition of Late Sodium Current: A Novel Target to Treat Cardiac Arrhythmias

Proarrhythmic Potential of Low-risk Drugs That Affect the Ventricular Repolarization

Classification of antiarrhythmic agents: electropharmacologic basis and clinical relevance

Research Progress on Natural Products’ Therapeutic Effects on Atrial Fibrillation by Regulating Ion Channels

Arrhythmogenic Ion-Channel Remodeling in the Heart: Heart Failure, Myocardial Infarction, and Atrial Fibrillation

Natural products as the calcium channel blockers for the treatment of arrhythmia: Advance and prospect

Structural basis for inhibition of a voltage-gated Ca2+ channel by Ca2+ antagonist drugs

Proarrhythmic and Antiarrhythmic Effects of Multiple Ion Channel Inhibitors Modulated by the Late Sodium Current